Helix Biomedix Inc. announced unaudited earnings results for the year ended December 31, 2011. For the year, the company's revenue increased 122% to a record $1.9 million, compared to $0.85 million for 2010. The year-over-year increase in revenue reflected a 52% increase in licensing revenue and a 120% increase in peptide and consumer product sales to non-affiliates. In addition, consumer product sales to NuGlow Cosmaceuticals, LLC, an affiliated direct-response company, increased to $0.48 million in 2011. Net loss and comprehensive loss for the year was $2.5 million, or $0.05 per basic and diluted share, compared to $7.7 million or $0.28 per basic and diluted share for 2010. The decrease in net loss for 2011 compared to the prior year reflected higher revenue combined with a reduction of $4.7 million in interest and other expenses related to the company's convertible debt that was converted or repaid in the fourth quarter of 2010. Loss from operations was $2.4 million compared with $2.96 million a year ago.